About all

Heparin interactions. Heparin: Uses, Dosage, Interactions, and Side Effects – Comprehensive Guide

What are the primary uses of heparin. How is heparin dosage determined. What are the major side effects of heparin. How does heparin interact with other medications. What precautions should be taken when using heparin.

Содержание

Understanding Heparin: A Powerful Anticoagulant

Heparin is a widely used anticoagulant medication that plays a crucial role in preventing blood clots. This injectable drug is derived from animal tissues, typically porcine (pig) intestines, and is available in various concentrations. Heparin works by interfering with the blood clotting process, making it an essential treatment for numerous medical conditions.

How does heparin work?

Heparin functions by binding to and activating antithrombin III, a natural protein in the blood that inhibits several enzymes involved in the coagulation cascade. This action effectively prevents the formation of new blood clots and stops existing clots from growing larger.

Primary Uses of Heparin in Medical Practice

Heparin is employed in various medical scenarios due to its rapid onset of action and effectiveness in preventing thrombosis. Here are some of the primary uses of heparin:

  • Treatment and prevention of deep vein thrombosis (DVT)
  • Management of pulmonary embolism
  • Prevention of blood clots during surgery and certain medical procedures
  • Treatment of unstable angina and acute coronary syndrome
  • Anticoagulation during hemodialysis and extracorporeal circulation

Can heparin be used during pregnancy?

Heparin is often the anticoagulant of choice for pregnant women who require blood thinning therapy. Unlike some other anticoagulants, heparin does not cross the placenta, making it safer for the developing fetus. However, its use during pregnancy should always be under strict medical supervision.

Dosage and Administration of Heparin

The dosage of heparin varies significantly depending on the specific medical condition, patient characteristics, and the type of heparin being used. It’s crucial to understand that heparin administration requires careful monitoring and adjustment.

How is heparin typically administered?

Heparin is most commonly administered via intravenous (IV) infusion or subcutaneous injection. The route of administration depends on the urgency of the anticoagulation effect needed and the specific medical situation.

  1. Intravenous administration: Used for immediate anticoagulation effect
  2. Subcutaneous injection: Employed for longer-term anticoagulation management

What factors influence heparin dosage?

Several factors can affect the appropriate dosage of heparin for an individual patient:

  • Patient’s weight
  • Kidney function
  • Liver function
  • Age
  • Presence of other medical conditions
  • Concurrent medications

Due to these variables, heparin therapy often requires frequent monitoring of blood coagulation parameters, such as the activated partial thromboplastin time (aPTT), to ensure the correct level of anticoagulation is maintained.

Potential Side Effects and Risks of Heparin Use

While heparin is an effective and widely used medication, it’s not without potential side effects and risks. Understanding these is crucial for both healthcare providers and patients.

What are the most common side effects of heparin?

Common side effects of heparin include:

  • Bleeding or bruising at the injection site
  • Mild pain or irritation at the injection site
  • Elevated liver enzymes
  • Allergic reactions (less common)

Are there any serious risks associated with heparin use?

Yes, there are several serious risks that patients and healthcare providers should be aware of:

  1. Heparin-induced thrombocytopenia (HIT): A potentially life-threatening condition where heparin paradoxically increases the risk of blood clots while lowering platelet counts
  2. Major bleeding events: Including gastrointestinal bleeding, intracranial hemorrhage, or retroperitoneal bleeding
  3. Osteoporosis: Long-term use of heparin can lead to decreased bone density
  4. Hyperkalemia: Elevated potassium levels in the blood

These risks underscore the importance of careful monitoring and appropriate patient selection for heparin therapy.

Heparin Interactions: Navigating the Complex Web

Heparin has a significant number of known drug interactions, which can affect its efficacy or increase the risk of side effects. Understanding these interactions is crucial for safe and effective use of the medication.

How many drug interactions does heparin have?

According to the provided information, heparin has 224 known drug interactions. These are categorized as follows:

  • 58 major interactions
  • 143 moderate interactions
  • 23 minor interactions

This extensive list of interactions highlights the importance of a thorough medication review before initiating heparin therapy.

Which medications have major interactions with heparin?

Some of the medications known to have major interactions with heparin include:

  • Warfarin (Coumadin)
  • Apixaban (Eliquis)
  • Enoxaparin (Lovenox)
  • Clopidogrel (Plavix)

These interactions can potentially increase the risk of bleeding or affect the anticoagulant effect of heparin. It’s crucial for healthcare providers to carefully consider these interactions when prescribing heparin.

Disease Interactions and Heparin: Important Considerations

Certain medical conditions can affect the safety and efficacy of heparin therapy. Understanding these disease interactions is vital for appropriate patient management.

Which diseases interact with heparin?

The provided information lists seven disease interactions with heparin:

  1. Peptic ulcer disease
  2. Active bleeding
  3. Hypertension
  4. Prematurity
  5. Renal dysfunction
  6. Thrombocytopenia
  7. Hyperkalemia

These conditions may either increase the risk of heparin-related complications or be exacerbated by heparin use. Careful consideration and monitoring are necessary when using heparin in patients with these conditions.

How does renal dysfunction affect heparin therapy?

Renal dysfunction can significantly impact heparin therapy in several ways:

  • Altered drug clearance: Impaired kidney function can lead to decreased clearance of heparin, potentially leading to drug accumulation and increased risk of bleeding
  • Dosage adjustments: Patients with renal dysfunction may require lower doses of heparin to achieve the desired anticoagulant effect
  • Increased monitoring: More frequent monitoring of coagulation parameters may be necessary to ensure safe and effective anticoagulation

Heparin Formulations and Concentrations

Heparin is available in various formulations and concentrations, each designed for specific clinical situations. Understanding these differences is crucial for proper administration and dosing.

What are the common concentrations of heparin?

Based on the information provided, heparin is typically available in the following concentrations:

  • 1,000 units/mL
  • 5,000 units/mL
  • 10,000 units/mL

These different concentrations allow for flexibility in dosing and administration, depending on the specific clinical need and route of administration.

How is heparin typically packaged?

Heparin is usually supplied as a clear, colorless solution in vials. The packaging is designed to maintain sterility and allow for easy withdrawal of the medication. It’s important to note that different formulations may have specific storage requirements, such as refrigeration, to maintain stability.

Monitoring Heparin Therapy: Ensuring Safety and Efficacy

Given the potent anticoagulant effects of heparin and its narrow therapeutic window, careful monitoring is essential to ensure both safety and efficacy of the treatment.

What tests are used to monitor heparin therapy?

Several laboratory tests are commonly used to monitor heparin therapy:

  1. Activated Partial Thromboplastin Time (aPTT): This is the most common test used to monitor unfractionated heparin therapy
  2. Anti-Factor Xa Assay: Used to monitor low molecular weight heparin therapy and sometimes unfractionated heparin
  3. Platelet Count: Monitored to detect heparin-induced thrombocytopenia
  4. Heparin Anti-Xa Level: Provides a direct measurement of heparin activity in the blood

How often should heparin therapy be monitored?

The frequency of monitoring depends on various factors, including:

  • Type of heparin used (unfractionated vs. low molecular weight)
  • Route of administration
  • Patient’s clinical condition
  • Stability of previous test results

Initially, monitoring may be performed every few hours until the desired anticoagulation effect is achieved. Once stabilized, monitoring frequency can often be reduced to daily or every other day, depending on the clinical situation.

Reversing Heparin’s Effects: Emergency Management

In cases of excessive anticoagulation or bleeding complications, it may be necessary to reverse the effects of heparin quickly. Understanding the options for reversal is crucial for managing potential emergencies.

How can the anticoagulant effects of heparin be reversed?

The primary agent used to reverse heparin’s effects is protamine sulfate. This medication works by binding to heparin, forming a stable complex that lacks anticoagulant activity. The process of reversing heparin’s effects involves:

  1. Discontinuing heparin administration
  2. Calculating the appropriate dose of protamine sulfate based on the amount of heparin received
  3. Administering protamine sulfate slowly via intravenous injection
  4. Monitoring coagulation parameters to ensure successful reversal

It’s important to note that protamine sulfate itself can have anticoagulant effects if given in excess, so careful dosing is crucial.

Are there any risks associated with heparin reversal?

While protamine sulfate is generally effective and well-tolerated, there are some potential risks to consider:

  • Allergic reactions: Some patients may experience allergic reactions to protamine sulfate, ranging from mild to severe
  • Hypotension: Rapid administration of protamine sulfate can cause a sudden drop in blood pressure
  • Rebound anticoagulation: In some cases, the heparin-protamine complex may dissociate over time, leading to a recurrence of anticoagulation effects

Due to these potential risks, heparin reversal should be performed under close medical supervision, with careful monitoring of the patient’s clinical status and coagulation parameters.

Heparin Interactions Checker – Drugs.com

Print

Save

There are 224 drugs known to interact with
heparin, along with
7 disease interactions, and 1 alcohol/food interaction.

Of the total drug interactions,
58 are major, 143 are moderate, and 23 are minor.

Does heparin interact with my other drugs?

Enter other medications to view a detailed report.

  • View all 224 medications that may interact with heparin
  • View heparin alcohol/food interactions (1)
  • View heparin disease interactions (7)

Most frequently checked interactions

View interaction reports for heparin and the medicines listed below.

  • Major
  • Moderate
  • Minor
  • Unknown
  • Ativan (lorazepam)
  • Benadryl (diphenhydramine)
  • Cardizem (diltiazem)
  • Colace (docusate)
  • Combivent (albuterol / ipratropium)
  • Coumadin (warfarin)
  • Dilaudid (hydromorphone)
  • Eliquis (apixaban)
  • Lantus (insulin glargine)
  • Lasix (furosemide)
  • Lipitor (atorvastatin)
  • Lopressor (metoprolol)
  • Lovenox (enoxaparin)
  • MiraLAX (polyethylene glycol 3350)
  • Norco (acetaminophen / hydrocodone)
  • Normal Saline Flush (sodium chloride)
  • Norvasc (amlodipine)
  • Paracetamol (acetaminophen)
  • Percocet (acetaminophen / oxycodone)
  • Phenergan (promethazine)
  • Plavix (clopidogrel)
  • Protonix (pantoprazole)
  • Rocephin (ceftriaxone)
  • Synthroid (levothyroxine)
  • Tylenol (acetaminophen)
  • Vitamin B12 (cyanocobalamin)
  • Vitamin C (ascorbic acid)
  • Vitamin D3 (cholecalciferol)
  • Xanax (alprazolam)
  • Zofran (ondansetron)

Heparin alcohol/food interactions

There is 1 alcohol/food interaction with heparin.

Heparin disease interactions

There are 7 disease interactions with heparin which include:

  • peptic ulcer disease
  • active bleeding
  • hypertension
  • prematurity
  • renal dysfunction
  • thrombocytopenia
  • hyperkalemia

Report options

Loading…

QR code containing a link to this page

More about heparin

  • heparin consumer information
  • Compare alternatives
  • Pricing & coupons
  • Reviews (2)
  • Latest FDA alerts (18)
  • Side effects
  • Dosage information
  • Patient tips
  • During pregnancy
  • Drug class: heparins
  • Breastfeeding
  • En español

Related treatment guides

  • Angina
  • Anticoagulation During Pregnancy
  • Antiphospholipid Syndrome
  • Deep Vein Thrombosis

Drug Interaction Classification
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
MajorHighly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
ModerateModerately clinically significant. Usually avoid combinations; use it only under special circumstances.
MinorMinimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
UnknownNo interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Heparin (Porcine) Injection: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: Shape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL (1 mL) injection cartridge

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 20,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL injection solution

Color: clearShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 10,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 1,000 unit/mL injection solution

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

heparin (porcine) 5,000 unit/mL (1 mL) injection cartridge

Color: colorlessShape: Imprint:

This medicine is a colorless, clear, vial

Heparin sodium drug interactions with other drugs (compatibility) | Vidal.

ru

Heparin sodium drug interactions with other drugs (compatibility) | Vidal.ru – a directory of medicines

Effects when used simultaneously with drugs
Abciximab Risk of bleeding. With simultaneous use, monitoring of the APTT is required.
Oral anticoagulants (vitamin K antagonists) Concomitant use of oral anticoagulants and low molecular weight heparins increases the risk of bleeding due to the additive anticoagulant effect. Both heparin and warfarin prolong the aPTT and prothrombin time. This disorder is recommended to be considered taking into account the therapeutic effect, since normal coagulation values ​​do not reflect the risk of bleeding. To reduce distortion in the determination of prothrombin time due to bolus intravenous heparin, an interval of at least 5-6 hours should be observed between the last administration of heparin and blood sampling.
NSAIDs Risk of hemorrhagic complications due to simultaneous inhibition of blood coagulation and platelet aggregation. If simultaneous use cannot be avoided, then constant monitoring of the patient’s condition is required.
Dextran Increased risk of bleeding due to antithrombotic and antiplatelet properties of dextran. The combination should be avoided unless the potential benefit of therapy outweighs the risk of bleeding, in which case an appropriate dose reduction of heparin is required.
Probenecid May increase the effects of heparin under the influence of probenecid and the development of bleeding.
Salicylates It has been established that the use of acetylsalicylic acid during heparin therapy increases the risk of bleeding by 2. 5 times. Due to antiplatelet and antithrombotic properties, salicylates can potentiate the anticoagulant effect of heparin, which increases the risk of bleeding. In addition, the ulcerogenic effect of salicylates may increase the risk of bleeding from the gastrointestinal tract. The use of this combination is characterized by a high risk, therefore, if combination therapy is necessary, the expected benefit and potential risk should be carefully evaluated. If combined use is necessary, then constant monitoring of the patient’s condition is required.

Our website uses cookies to improve your user experience and performance, as well as marketing activities.
By continuing, you agree to the use of cookies.
Ok

Order a drug

Heparin instructions for use: indications, contraindications, side effects – description of Heparin solution for injections.

5 thousand IU / ml: 1 ml or 2 ml amp. 5 or 10 pieces, 5 ml vial 5 or 50 pcs. (4363)

💊 Composition of the drug Heparin

✅ Use of the drug Heparin

Save

Search for analogues

Interaction

Description of the active ingredients of the preparation

Heparin
(Heparin)

The scientific information provided is general and cannot be used to make decisions.
decisions about the use of a particular drug.

Update date: 2019.12.04

Marketing authorization holder:

SYNTHESIS JSC
(Russia)

ATX code:

B01AB01

(Heparin)

Active substance:
sodium heparin
(heparin sodium)

Rec. INN

WHO registered

Dosage form

Heparin

Injection solution 5 thousand IU / ml: 1 ml or 2 ml amp. 5 or 10 pieces, 5 ml vial 5 or 50 pcs.

reg. No.: R N000116/01
dated 01.10.07
– Indefinitely

Release form, packaging and composition
drug Heparin

5 ml – bottles (5) – packs of cardboard.
5 ml – bottles (50) – cardboard boxes.
5 ml vials.
5 ml – bottles (5) – contour plastic packaging (1) – packs of cardboard.
1 ml – ampoules (5) – blister strip packs (2) – cardboard packs.
2 ml – ampoules (5) – blister strip packs (1) – cardboard packs.
5 ml – ampoules (5) – blister strip packs (1) – cardboard packs.
5 ml – ampoules (5) – blister strip packs (2) – cardboard packs.
2 ml – ampoules (5) – blister strip packs (2) – cardboard packs.
1 ml – ampoules (5) – blister packs (1) – cardboard packs.

Clinical and pharmacological group:

Direct acting anticoagulant – medium molecular weight heparin

Pharmacotherapeutic group:

Direct acting anticoagulant

Pharmacological action

Direct acting anticoagulant belongs to the group of medium molecular weight heparins. In blood plasma, it activates antithrombin III, accelerating its anticoagulant effect. Violates the transition of prothrombin to thrombin, inhibits the activity of thrombin and activated factor X, to some extent reduces platelet aggregation.

For unfractionated standard heparin, the ratio of antiplatelet activity (anti-factor Xa) to anticoagulant activity (APTT) is 1:1.

Increases renal blood flow; increases the resistance of cerebral vessels, reduces the activity of cerebral hyaluronidase, activates lipoprotein lipase and has a hypolipidemic effect. Reduces the activity of surfactant in the lungs, suppresses excessive synthesis of aldosterone in the adrenal cortex, binds adrenaline, modulates the ovarian response to hormonal stimuli, enhances the activity of parathyroid hormone. As a result of interaction with enzymes, it can increase the activity of brain tyrosine hydroxylase, pepsinogen, DNA polymerase and reduce the activity of myosin ATPase, pyruvate kinase, RNA polymerase, pepsin.

Heparin has been shown to have immunosuppressive activity.

In patients with coronary artery disease (in combination with acetylsalicylic acid) reduces the risk of acute coronary artery thrombosis, myocardial infarction and sudden death. Reduces the frequency of recurrent heart attacks and mortality in patients with myocardial infarction. In high doses, it is effective for pulmonary embolism and venous thrombosis, in small doses it is effective for the prevention of venous thromboembolism, incl. after surgical operations.

With intravenous administration, blood coagulation slows down almost immediately, with intramuscular injection – after 15-30 minutes, with s / c – after 20-60 minutes, after inhalation, the maximum effect is after a day; the duration of the anticoagulant action, respectively, is 4-5, 6, 8 hours and 1-2 weeks, the therapeutic effect – prevention of thrombosis – lasts much longer. Deficiency of antithrombin III in plasma or at the site of thrombosis may reduce the antithrombotic effect of heparin.

Pharmacokinetics

After subcutaneous administration C max of the active substance in plasma is observed after 3-4 hours. Heparin does not penetrate the placenta well due to its large molecular weight. Not excreted in breast milk.

T 1/2 from plasma is 30-60 min.

Indications of the active substances of the drug

Heparin

Prevention and therapy: deep vein thrombosis, pulmonary embolism (including in peripheral vein diseases), coronary artery thrombosis, thrombophlebitis, unstable angina, acute myocardial infarction, atrial fibrillation (including accompanied by embolism), DIC, prevention and therapy of microthrombosis and microcirculation disorders, renal vein thrombosis, hemolytic uremic syndrome, mitral heart disease (thrombosis prevention), bacterial endocarditis, glomerulonephritis, lupus nephritis.

Prevention of blood coagulation during operations using extracorporeal methods of circulation, during hemodialysis, hemosorption, peritoneal dialysis, cytapheresis, forced diuresis, when washing venous catheters.

Preparation of non-clotting blood samples for laboratory purposes and blood transfusion.

Open list of ICD-10 codes

D59.3 Hemolytic uremic syndrome
D65 Disseminated intravascular coagulation [defibrination syndrome]
I20.0 Unstable angina
I21 Acute myocardial infarction
I26 Pulmonary embolism
I33.9 Acute endocarditis, unspecified
I34. 0 Mitral (valvular) insufficiency
I48 Atrial fibrillation and flutter
I74 Arterial embolism and thrombosis
I80 Phlebitis and thrombophlebitis
I82 Embolism and thrombosis of other veins
N00 Acute nephritic syndrome (acute glomerulonephritis)
N03 Chronic nephritic syndrome
N08.5 Glomerular lesions in systemic connective tissue diseases
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified

Dosing regimen

The method of administration and dosing regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

Individual, depending on the dosage form used, indications, clinical situation and age of the patient.

Side effects

On the part of the blood coagulation system: possible bleeding of the gastrointestinal tract and urinary tract, bleeding at the injection site, in areas subjected to pressure, from surgical wounds, as well as hemorrhages in other organs, hematuria, thrombocytopenia.

From the digestive system: nausea, loss of appetite, vomiting, diarrhea, increased activity of liver transaminases.

Allergic reactions: flushing of the skin, drug fever, urticaria, rhinitis, pruritus and sensation of heat in the soles, bronchospasm, collapse, anaphylactic shock.

On the part of the blood coagulation system: thrombocytopenia (may be severe up to death) with subsequent development of skin necrosis, arterial thrombosis, accompanied by the development of gangrene, myocardial infarction, stroke.

From the musculoskeletal system: with prolonged use – osteoporosis, spontaneous fractures, soft tissue calcification.

Local reactions: irritation, pain, hyperemia, hematoma and ulceration at the injection site.

Other: transient alopecia, hypoaldosteronism.

Contraindications for use

Bleeding, diseases accompanied by impaired blood coagulation, suspected intracranial hemorrhage, cerebral aneurysm, hemorrhagic stroke, dissecting aortic aneurysm, antiphospholipid syndrome, malignant arterial hypertension, subacute bacterial endocarditis, erosive ulcerative lesions of the gastrointestinal tract , severe lesions of the liver parenchyma, cirrhosis of the liver with varicose veins of the esophagus, malignant neoplasms in the liver, shock conditions, recent surgical interventions on the eyes, brain, prostate, liver and biliary tract, condition after spinal cord puncture, menstruation, threatened miscarriage, childbirth (including recent), hypersensitivity to heparin.

Use during pregnancy and lactation

Use during pregnancy is possible only under strict indications, under close medical supervision.

Contraindication: threatened miscarriage, childbirth (including recent).

Can be used during breastfeeding if indicated.

Use for violations of liver function

Contraindications: severe lesions of the liver parenchyma, cirrhosis of the liver with varicose veins of the esophagus, malignant neoplasms in the liver.

Use for impaired renal function

Used when indicated in patients with severe kidney disease.

Use in children

May be used in children if indicated.

Use in elderly patients

Use with caution in elderly patients (over 60 years, especially in women).

Special instructions

Use with caution in patients suffering from polyvalent allergies (including bronchial asthma), arterial hypertension, dental procedures, diabetes mellitus, endocarditis, pericarditis, in the presence of an intrauterine contraceptive, with active tuberculosis, radiation therapy, liver failure, chronic renal failure, in elderly patients (over 60 years, especially women).

IM administration of heparin is not recommended due to the possibility of developing a hematoma, as well as IM administration of other drugs during treatment with heparin.

Use with caution externally for bleeding and conditions of increased bleeding, thrombocytopenia.

During treatment with heparin, monitoring of blood coagulation parameters is necessary.

Only normal saline is used to dilute heparin.

With the development of severe thrombocytopenia (a decrease in the number of platelets by 2 times from the original number or below 100,000 / µl), heparin should be urgently discontinued.

The risk of bleeding can be minimized with careful evaluation of contraindications, regular laboratory monitoring of blood clotting, and adequate dosing.

Drug interactions

The anticoagulant effect of heparin is enhanced by the simultaneous use of anticoagulants, antiplatelet agents and NSAIDs.

Ergot alkaloids, thyroxine, tetracycline, antihistamines, and nicotine reduce the effect of heparin.

Leave a Reply

Your email address will not be published. Required fields are marked *